Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, Kelder A, Snel AN, Zweegman S, Ossenkoppele GJ, Smit L. Schuurhuis GJ, et al. Among authors: terwijn m. PLoS One. 2013 Nov 11;8(11):e78897. doi: 10.1371/journal.pone.0078897. eCollection 2013. PLoS One. 2013. PMID: 24244383 Free PMC article. Clinical Trial.
Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.
Terwijn M, Kelder A, Snel AN, Rutten AP, Scholten WJ, Oussoren YJ, Van De Loosdrecht AA, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ. Terwijn M, et al. Int J Lab Hematol. 2012 Aug;34(4):432-41. doi: 10.1111/j.1751-553X.2012.01416.x. Epub 2012 Apr 4. Int J Lab Hematol. 2012. PMID: 22471741
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ. Terwijn M, et al. J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23. J Clin Oncol. 2013. PMID: 24062400 Clinical Trial.
High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.
van den Ancker W, van Luijn MM, Chamuleau ME, Kelder A, Feller N, Terwijn M, Zevenbergen A, Schuurhuis GJ, van Ham SM, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. van den Ancker W, et al. Among authors: terwijn m. Leuk Res. 2014 Jun;38(6):691-3. doi: 10.1016/j.leukres.2014.03.014. Epub 2014 Mar 25. Leuk Res. 2014. PMID: 24731748
Towards cure of CML: why we need to know more about CML stem cells?
Janssen JJ, Schuurhuis GJ, Terwijn M, Ossenkoppele GJ. Janssen JJ, et al. Among authors: terwijn m. Curr Stem Cell Res Ther. 2009 Sep;4(3):224-36. doi: 10.2174/157488809789057428. Curr Stem Cell Res Ther. 2009. PMID: 19492977 Review.
Uncommon lineage switch warrants immunophenotyping even in relapsing leukemia.
van den Ancker W, Terwijn M, Regelink J, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA, Zweegman S. van den Ancker W, et al. Among authors: terwijn m. Leuk Res. 2009 Jul;33(7):e77-80. doi: 10.1016/j.leukres.2008.11.029. Epub 2009 Jan 20. Leuk Res. 2009. PMID: 19157544 No abstract available.
11 results